Sequential CD19 and BCMA‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma

Sequential CD19 and BCMA‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma

Abstract The low rate of durable response against relapsed and/or refractory multiple myeloma (RRMM) in recent studies indicates that chimeric antigen receptor T‐cell (CART) treatment is yet to be optimized. This study aims to investigate the safety and efficacy of sequential infusion of CD19‐CART a...

Full description

Bibliographic Details
Main Authors: Lingzhi Yan, Su Qu, Jingjing Shang, Xiaolan Shi, Liqing Kang, Nan Xu, Mingqing Zhu, Jin Zhou, Song Jin, Weiqin Yao, Ying Yao, Guanghua Chen, Huirong Chang, Xiaming Zhu, Lei Yu, Depei Wu, Chengcheng Fu
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Cancer Medicine
Subjects:
chimeric antigen receptor T (CAR T) cell
dose‐escalation
efficacy
multiple myeloma
relapsed and/or refractory
safety
Online Access:https://doi.org/10.1002/cam4.3624

Internet

https://doi.org/10.1002/cam4.3624

Similar Items